Skip to main content

Advertisement

SpringerLink
Log in

Predictors of response to fesoterodine in patients with an overactive bladder

  • Original Article
  • Published:
Journal of Inclusion Phenomena and Macrocyclic Chemistry Aims and scope Submit manuscript

Abstract

An analysis has been conducted of the predictors of the fesoterodine treatment response for female patients with overactive bladder (OAB) syndrome. Eighty-seven women diagnosed with OAB and who had undergone 12 weeks of treatment with fesoterodine (4 mg/day) were involved. Prior to treatment, the patients were evaluated through their medical history, physical examinations, urine analysis, urine cultures, voiding diaries and urodynamic studies. The voiding diaries and personal interviews concerning urinary symptoms were analyzed 12 weeks after treatment. Seventy-nine (82.3%) women experienced improvement of OAB symptoms (Improvement group), and for seventeen (17.7%) women the symptoms remained unchanged or worsened (Persistence group) after treatment. In the urodynamic studies, detrusor overactivity was noted in 37 (46.8%) patients of the improvement group and 3 (17.6%) of the persistence group. The number of patients who showed detrusor overactivity in urodynamic studies before the treatment was significantly larger in the improvement group. Maximum detrusor pressure and detrusor pressure at maximum flow were higher in the persistence group but not to statistically significant levels. In pre-treatment voiding diaries, the number of urgencies per day was significantly larger in the improvement group. The efficacy of fesoterodine treatment for female OAB problems was found to be be associated with the frequency of urgency and detrusor overactivity. Thus, both voiding diaries and urgency/detrusor symptom records may aid in predicting the efficacy of fesoterodine treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sand, P.K., Morrow, J.D., Bavendam, T., Creanga, D.L., Nitti, V.W.: Efficacy and tolerability of fesoterodine in women with overactive bladder. Int. Urogynecol. J. 20, 827–835 (2009)

    Article  Google Scholar 

  2. Chapple, C., Kerrebroeck, P.V., Tubaro, A., Haag-Molkenteller, C., Forst, H.-T., Massow, U., Wange, J., Brodsky, M.: Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Europ. Urol. 52, 1204–1212 (2007)

    Article  CAS  Google Scholar 

  3. Nitti, V.W., Dmochowski, R., Sand, P.K., Forst, H.-T., Haag-Molkenteller, C., Massow, U., Wang, J., Brodsky, M., Bavendam, T.: Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J. Urol. 178, 2488–2494 (2007)

    Article  CAS  Google Scholar 

  4. Kraus, S.R., Ruiz-Cerdá, J.L., Martire, D., Wang, J.T., Wagg, A.S.: Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 76, 1350–1357 (2010)

    Article  Google Scholar 

  5. Cardozo, L., Khullar, V., El-Tahtawy, A., Guan, Z., Malhotra, B., Staskin, D.: Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. BMC Urol. 10, 14 (2010)

    Article  Google Scholar 

  6. Ellsworth, P., Berriman, S.J., Brodsky, M.: Fesoterodine: a new agent for treating overactive bladder. Amer. J. Managed Care. 15, 4 (2009)

    Google Scholar 

  7. Herschorn Sender, J., Jones, S., Oelke, M., MacDiarmid, S., Wang, J.T., Guan, Z.: Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology. 75, 1149–1155 (2010)

    Article  CAS  Google Scholar 

  8. Meek, P.D., Evang, S.D., Tadrous, M., Roux-Lirange, D., Triller, D.M., Gumustop, B.: Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig. Dis. Sci. 56, 7–18 (2011)

    Article  CAS  Google Scholar 

  9. Wyndaele, J.-J., Goldfischer, E.R., Morrow, J.D., Gong, J., Tseng, L.-J., Guan, Z., Choo, M.-S.: Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int. J. Clin. Pract. 63, 560–567 (2009)

    Article  CAS  Google Scholar 

  10. Ellsworth, P.: Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag 5, 869–876 (2009)

    Article  CAS  Google Scholar 

  11. Van Kerrebroeck, P.E.V., Heesakkers, J., Berriman, S., Aiyer, L.P., Carlsson, M., Guan, Z.: Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int. J. Clin. Pract. 64, 584–593 (2010)

    Article  Google Scholar 

  12. Malhotra, B.K., Crownover, P.H., La Badie, R., Glue, P., MacDiarmid, S.A.: The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. Eur. J. Clin. Pharmacol. 66, 171–176 (2010)

    Article  CAS  Google Scholar 

  13. Chapple, C.R., Van Kerrebroeck, P.E., Jünemann, K.-P., Wang, J.T., Brodsky, M.: Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 102, 1128–1132 (2008)

    Article  CAS  Google Scholar 

  14. Goldman, H.B., Morrow, J.D., Gong, J., Tseng, L.-J., Schneider, T.: Early onset of fesoterodine efficacy in subjects with overactive bladder. BJU Int. 107, 598–602 (2010)

    Article  Google Scholar 

  15. Herschorn, S., Swift, S., Guan, Z., Carlsson, M., Morrow, J.D., Brodsky, M., Gong, J.: Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 105, 58–66 (2009)

    Article  Google Scholar 

  16. Acquadro, C., Kopp, Z., Coyne, K.S., Corcos, J., Tubaro, A., Choo, M.S.: Translating overactive bladder questionnaires in 14 languages. Urology. 67, 536–540 (2006)

    Article  Google Scholar 

  17. Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., Wein, A.: The standardization of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol. Urodyn. 21, 167–178 (2002)

    Article  Google Scholar 

  18. Abrams, P., Blaivas, J.G., Stanton, S.L.: The standardization of terminology of low urinary tract function recommended by the International Continence Society. Int. Urogynecol. J. 1, 45–58 (1990)

    Article  Google Scholar 

  19. Milsom, I., Abrams, P., Cardozo, L., Roberts, R.G., Thuroff, J., Wein, A.J.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87, 760–766 (2001)

    Article  CAS  Google Scholar 

  20. Kelleher, C.J., Reese, P.R., Pleil, A.M., Okano, G.J.: Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am. J. Manag. Care 8, S608–S615 (2002)

    Google Scholar 

  21. Liberman, J.N., Hunt, T.L., Stewart, W.F.: Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology 57, 1044–1050 (2001)

    Article  CAS  Google Scholar 

  22. Coyne, K., Revicki, D., Hunt, T.: Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual. Life Res. 11, 563–574 (2002)

    Article  CAS  Google Scholar 

  23. Kim, U.H., Kim, Y.H., Kim, M.E.: The prevalence and quality of life of overactive bladder and urinary incontinence in young women. Korean J. Urol. 45, 543–550 (2004)

    Google Scholar 

  24. Abrams, P., Wein, A.J.: Introduction: overactive bladder and its treatments. Urology. 55, 1–27 (2000)

    Article  Google Scholar 

  25. Milsom, I., Stewart, W., Thuroff, J.: The prevalence of overactive bladder. Amer. J. Manag. Care. S565–S573 (2000)

  26. Stewart, A.L., Hays, R.D., Ware Jr., J.E.: The MOS short form general health survey. Reliability and validity in a patient population. Med. Care 26, 724–735 (1998)

    Article  Google Scholar 

  27. Elving, L.B., Foldspang, A., Lam, G.W., Mommsen, S.: Descriptive epidemiology of urinary incontinence in 3, 100 women age 30–59. Scand. J. Urol. Nephrol. Suppl. 125, 37–43 (1989)

    CAS  Google Scholar 

  28. Goepel, M., Hoffmann, J.A., Piro, M., Rubben, H., Michel, M.C.: Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur. Urol. 41, 234–239 (2002)

    Article  Google Scholar 

  29. Lapitan, M.C., Chye, P.L.: The epidemiology of overactive bladder among females in Asia: a questionnaire survey. Int. Urogynecol. J. Pelvic. Floor Dysfunct 12, 226–231 (2001)

    Article  CAS  Google Scholar 

  30. Jackson, S.: The patient with an overactive bladder symptoms and quality of life issues. Urology. 50(6A Suppl), 18–22 (1997)

    Article  CAS  Google Scholar 

  31. Komaroff, A.L., Fagioli, L.R., Doolittle, T.H.: Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am. J. Med. 101, 281–290 (1996)

    Article  CAS  Google Scholar 

  32. Braverman, A.S., Ruggieri, M.R.Sr.: Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Amer. J. Physiol. Regul. Integr. Comp. Physiol. 285, R701–R708 (2003)

    Google Scholar 

Download references

Acknowledgments

We express our deep appreciation to Dr. Jack M. Harrowfield who has kindly improved the English of our manuscript.

Author information

Authors and Affiliations

  1. Department of Urology, Pusan National University School of Medicine, 1-10, Ami-Dong, Seo-Ku, Busan, 602-739, Korea

    Hyeon Woo Kim, Jeong Zoo Lee & Dong Gil Shin

Authors
  1. Hyeon Woo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeong Zoo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong Gil Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong Gil Shin.

Additional information

Dedicated to Professor Leonard F. Lindoy, a great chemist, on the occasion of his 75th birthday.

Appendix: OAB Screener

Appendix: OAB Screener

This questionnaire concerns how much you have been bothered by selected bladder symptoms during the past 4 weeks. Please circle the number that best describes the extent to which you were bothered by each symptom during the past 4 weeks. There are no right or wrong answers. Please be sure to answer every question

During the past 4 weeks, how bothered were you by…

Not at all

A little bit

Some what

Quite a bit

A great deal

A very great deal

1. Frequent urination during the daytime hours

0

1

2

3

4

5

2. An uncomfortable urge to urinate

0

1

2

3

4

5

3. A sudden urge to urinate with little or no warning

0

1

2

3

4

5

4. Accidental loss of small amounts of urine

0

1

2

3

4

5

5. Nighttime urination

0

1

2

3

4

5

6. Waking up at night because you had to urinate

0

1

2

3

4

5

7. An uncontrollable urge to urinate

0

1

2

3

4

5

8. Urine loss associated with a strong desire to urinate

0

1

2

3

4

5

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, H.W., Lee, J.Z. & Shin, D.G. Predictors of response to fesoterodine in patients with an overactive bladder. J Incl Phenom Macrocycl Chem 71, 517–522 (2011). https://doi.org/10.1007/s10847-011-0013-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10847-011-0013-8

Keywords

Search

Navigation